Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy-Reference-Cited by-同舟云学术

Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy

Published:2016-08-31 Issue:41 Volume:7 Page:67521-67531
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Park Haeseong¹²,Garrido-Laguna Ignacio³,Naing Aung¹,Fu Siqing¹,Falchook Gerald S.¹⁴,Piha-Paul Sarina A.¹,Wheler Jennifer J.¹,Hong David S.¹,Tsimberidou Apostolia M.¹,Subbiah Vivek¹,Zinner Ralph G.¹⁵,Kaseb Ahmed O.⁶,Patel Shreyaskumar⁷,Fanale Michelle A.⁸,Velez-Bravo Vivianne M.¹,Meric-Bernstam Funda¹,Kurzrock Razelle⁹,Janku Filip¹

Affiliation:

1. Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

2. Department of Internal Medicine (Division of Oncology), Washington University School of Medicine, St. Louis, MO, USA

3. Department of Internal Medicine (Division of Oncology), Huntsman Cancer Institute and University of Utah School of Medicine, Salt Lake City, UT, USA

4. Sarah Cannon Research Institute at HealthONE, Denver, CO, USA

5. Medical Oncology, Thomas Jefferson University and Jefferson University Hospitals, Philadelphia, PA, USA

6. Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

7. Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

8. Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

9. Center for Personalized Cancer Therapy, University of California San Diego Moores Cancer Center, San Diego, CA, USA

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 43 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Large-scale foundation model on single-cell transcriptomics;Nature Methods;2024-06-06

2. An Updated Comprehensive Pharmacovigilance Study of Drug‐Induced Thrombocytopenia Based on FDA Adverse Event Reporting System Data;The Journal of Clinical Pharmacology;2024-01-05

3. Large Scale Foundation Model on Single-cell Transcriptomics;2023-05-31

4. Clinical Experiences with Drugs Targeting m TOR;Precision Cancer Therapies, Volume 1 ‐ Targeting Oncogenic Drivers and Signaling Pathways in Lymphoid Malignancies;2023-03-15

5. Clinical Studies and Epi-Drugs in Various Cancer Types;Epigenetics and Human Health;2023